Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)
| Autor: | Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Gordon LI, Karmali R, Kaplan JB] Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. [Popat R] Department of Haematology, NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK. [Burris HA 3rd] Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA. [Ferrari S] Dipartimento di Oncologia ed Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy. [Carpio C] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bosch F] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
Cèl·lules B - Tumors - Tractament
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Sang - Malalties - Tractament Other subheadings::Other subheadings::/drug therapy [Other subheadings] Protein Kinase Inhibitors/adverse effects Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS] enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES] Humans Syk Kinase Other subheadings::/therapeutic use [Other subheadings] neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES] TAK-659 Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES] Vascular Endothelial Growth Factor Receptor-1 Manchester Cancer Research Centre acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS] Otros calificadores::/uso terapéutico [Otros calificadores] ResearchInstitutes_Networks_Beacons/mcrc Non-Hodgkin's lymphoma Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES] SYK inhibitor Treatment Outcome Oncology DLBCL Antineoplastic Combined Chemotherapy Protocols/therapeutic use Relapsed/refractory Proteïnes quinases - Inhibidors - Ús terapèutic Lymphoma Large B-Cell Diffuse/pathology |
| Zdroj: | Gordon, L I, Karmali, R, Kaplan, J B, Popat, R, Burris, H A, Ferrari, S, Madan, S, Patel, M R, Gritti, G, El-Sharkawi, D, Chau, F I, Radford, J, de Oteyza, J P, Zinzani, P L, Iyer, S P, Townsend, W, Miao, H, Proscurshim, I, Wang, S, Katyayan, S, Yuan, Y, Zhu, J, Stumpo, K, Shou, Y, Carpio, C & Bosch, F 2023, ' Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) ', Oncotarget, vol. 14, pp. 57-70 . https://doi.org/10.18632/oncotarget.28352 Scientia |
| DOI: | 10.18632/oncotarget.28352 |
| Popis: | Non-Hodgkin’s lymphoma; SYK inhibitor; Relapsed/refractory Linfoma no Hodgkin; Inhibidor de SYK; Recidivante/refractario Limfoma no Hodgkin; Inhibidor de SYK; Recaiguda/refractària We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). Patients with relapsed/refractory lymphoma for which no standard treatment was available received mivavotinib 60–120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity. A total of 124 patients with lymphoma, including 89 with DLBCL, were enrolled. Overall response rates (ORR) in response-evaluable patients were 45% (43/95) and 38% (26/69), respectively. Median duration of response was 28.1 months overall and not reached in DLBCL responders. In subgroups with DLBCL of germinal center B-cell (GCB) and non-GCB origin, ORR was 28% (11/40) and 58% (7/12), respectively. Median progression free survival was 2.0 and 1.6 months in the lymphoma and DLBCL cohorts, respectively. Grade ≥3 treatment-emergent adverse events occurred in 96% of all lymphoma patients, many of which were limited to asymptomatic laboratory abnormalities; the most common were increased amylase (29%), neutropenia (27%), and hypophosphatemia (26%). These findings support SYK as a potential therapeutic target for the treatment of patients with B-cell lymphomas, including DLBCL. This study was funded by Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|